tetano
Editor, Senior Moderator
Nat Med
. 2023 Jan 9.
doi: 10.1038/s41591-022-02185-4. Online ahead of print.
A survey of COVID-19 vaccine acceptance across 23 countries in 2022
Jeffrey V Lazarus[SUP] 1 2 [/SUP], Katarzyna Wyka[SUP] 3 [/SUP], Trenton M White[SUP] 4 [/SUP], Camila A Picchio[SUP] 4 [/SUP], Lawrence O Gostin[SUP] 5 [/SUP], Heidi J Larson[SUP] 3 6 7 [/SUP], Kenneth Rabin[SUP] 3 [/SUP], Scott C Ratzan[SUP] 3 [/SUP], Adeeba Kamarulzaman[SUP] 8 [/SUP], Ayman El-Mohandes[SUP] 3 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continued to mutate and spread in 2022 despite the introduction of safe, effective vaccines and medications. Vaccine hesitancy remains substantial, fueled in part by misinformation. Our third study of Coronavirus Disease 2019 (COVID-19) vaccine hesitancy among 23,000 respondents in 23 countries (Brazil, Canada, China, Ecuador, France, Germany, Ghana, India, Italy, Kenya, Mexico, Nigeria, Peru, Poland, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Turkey, the United Kingdom and the United States), surveyed from 29 June to 10 July 2022, found willingness to accept vaccination at 79.1%, up 5.2% from June 2021. Hesitancy increased in eight countries, however, ranging from 1.0% (United Kingdom) to 21.1% (South Africa). Almost one in eight (12.1%) vaccinated respondents are hesitant about booster doses. Overall support for vaccinating children under 18 years of age increased slightly but declined among parents who were personally hesitant. Almost two in five (38.6%) respondents reported paying less attention to new COVID-19 information than previously, and support for vaccination mandates decreased. Almost a quarter (24%) of those who became ill reported taking medications to combat COVID-19 symptoms. Vaccination remains a cornerstone of the COVID-19 pandemic response, but broad public support remains elusive. These data can be used by health system decisionmakers, practitioners, advocates and researchers to address COVID-19 vaccine hesitancy more effectively.
. 2023 Jan 9.
doi: 10.1038/s41591-022-02185-4. Online ahead of print.
A survey of COVID-19 vaccine acceptance across 23 countries in 2022
Jeffrey V Lazarus[SUP] 1 2 [/SUP], Katarzyna Wyka[SUP] 3 [/SUP], Trenton M White[SUP] 4 [/SUP], Camila A Picchio[SUP] 4 [/SUP], Lawrence O Gostin[SUP] 5 [/SUP], Heidi J Larson[SUP] 3 6 7 [/SUP], Kenneth Rabin[SUP] 3 [/SUP], Scott C Ratzan[SUP] 3 [/SUP], Adeeba Kamarulzaman[SUP] 8 [/SUP], Ayman El-Mohandes[SUP] 3 [/SUP]
Affiliations
- PMID: 36624316
- DOI: 10.1038/s41591-022-02185-4
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continued to mutate and spread in 2022 despite the introduction of safe, effective vaccines and medications. Vaccine hesitancy remains substantial, fueled in part by misinformation. Our third study of Coronavirus Disease 2019 (COVID-19) vaccine hesitancy among 23,000 respondents in 23 countries (Brazil, Canada, China, Ecuador, France, Germany, Ghana, India, Italy, Kenya, Mexico, Nigeria, Peru, Poland, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Turkey, the United Kingdom and the United States), surveyed from 29 June to 10 July 2022, found willingness to accept vaccination at 79.1%, up 5.2% from June 2021. Hesitancy increased in eight countries, however, ranging from 1.0% (United Kingdom) to 21.1% (South Africa). Almost one in eight (12.1%) vaccinated respondents are hesitant about booster doses. Overall support for vaccinating children under 18 years of age increased slightly but declined among parents who were personally hesitant. Almost two in five (38.6%) respondents reported paying less attention to new COVID-19 information than previously, and support for vaccination mandates decreased. Almost a quarter (24%) of those who became ill reported taking medications to combat COVID-19 symptoms. Vaccination remains a cornerstone of the COVID-19 pandemic response, but broad public support remains elusive. These data can be used by health system decisionmakers, practitioners, advocates and researchers to address COVID-19 vaccine hesitancy more effectively.